Literature DB >> 30381302

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Lionel Ades1, Agnès Guerci-Bresler2, Pascale Cony-Makhoul3, Laurence Legros4, Marie Sebert1, Thorsten Braun5, Jacques Delaunay6, Kristell Desseaux7, Sylvie Chevret7, Pierre Fenaux8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30381302      PMCID： PMC6442966          DOI： 10.3324/haematol.2018.203885

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

2.  Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.

Authors:  Fadi Braiteh; Andres O Soriano; Guillermo Garcia-Manero; David Hong; Marcella M Johnson; Leandro De Padua Silva; Hui Yang; Stefanie Alexander; Johannes Wolff; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

3.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

4.  Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

Authors:  Thomas Prebet; Zhuoxin Sun; Maria E Figueroa; Rhett Ketterling; Ari Melnick; Peter L Greenberg; James Herman; Mark Juckett; Mitchell R Smith; Lisa Malick; Elisabeth Paietta; Magdalena Czader; Mark Litzow; Janice Gabrilove; Harry P Erba; Steven D Gore; Martin S Tallman
Journal:  J Clin Oncol       Date:  2014-03-24       Impact factor: 44.544

5.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:  Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 6.  Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.

Authors:  Chong Gao; Jia Wang; Ya Li; Huan Zhao; Ruibai Li; Li Hou; Yayue Zhang; Shaodan Tian; Huan Liang; Chong Wang; Xinyi Chen; Jing Wang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
  6 in total
  2 in total

Review 1.  Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.

Authors:  Julia Stomper; John Charles Rotondo; Gabriele Greve; Michael Lübbert
Journal:  Leukemia       Date:  2021-05-06       Impact factor: 11.528

2.  Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?

Authors:  Andrew M Brunner; Geoffrey Fell; David P Steensma
Journal:  Blood Adv       Date:  2022-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.